Amgen announced the release of new data from a phase 3 study June 23 that showed its cholesterol drug Repatha reduced two key types of cholesterol by more than 50 percent in patients with Type 2 diabetes. Presented at the American Diabetes Association annual meeting, the study – dubbed Banting by the Thousand Oaks biotech…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
